Skip to main content
Contact Us
Subscribe
E-Edition
36°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
2025 Calendar Photos
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Olema Oncology
< Previous
1
2
Next >
Olema Oncology to Present New Palazestrant Clinical Data in Combination with CDK4/6 Inhibitors at the 2023 San Antonio Breast Cancer Symposium (SABCS)
November 28, 2023
From
Olema Oncology
Via
GlobeNewswire
Tickers
OLMA
Olema Oncology Reports Third Quarter 2023 Financial Results and Provides Corporate Update
November 07, 2023
From
Olema Oncology
Via
GlobeNewswire
Tickers
OLMA
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 02, 2023
From
Olema Oncology
Via
GlobeNewswire
Tickers
OLMA
Olema Oncology to Participate in Upcoming Investor Conferences in November
November 01, 2023
From
Olema Oncology
Via
GlobeNewswire
Tickers
OLMA
Olema Oncology Announces Positive Phase 2 Monotherapy Clinical Study Results for Palazestrant
October 22, 2023
From
Olema Oncology
Via
GlobeNewswire
Tickers
OLMA
Olema Oncology Appoints Oncology Biotech Executive Scott Garland to Board of Directors
October 17, 2023
From
Olema Oncology
Via
GlobeNewswire
Tickers
OLMA
Olema Oncology Announces Phase 2 Monotherapy Clinical Results to be Presented at the 2023 ESMO Congress
October 16, 2023
From
Olema Oncology
Via
GlobeNewswire
Tickers
OLMA
Olema Oncology KAT6 Inhibitor Compounds Demonstrate Potent Anti-Tumor Activity
October 12, 2023
From
Olema Oncology
Via
GlobeNewswire
Tickers
OLMA
Olema Oncology Announces Expansion of Collaboration Agreement with Novartis
October 10, 2023
From
Olema Oncology
Via
GlobeNewswire
Tickers
OLMA
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 03, 2023
From
Olema Oncology
Via
GlobeNewswire
Tickers
OLMA
Olema Oncology Announces New Preclinical KAT6 Inhibitor Data to be Presented at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
September 20, 2023
From
Olema Oncology
Via
GlobeNewswire
Tickers
OLMA
Olema Oncology to Participate in Upcoming Investor Conferences
September 06, 2023
From
Olema Oncology
Via
GlobeNewswire
Tickers
OLMA
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 05, 2023
From
Olema Oncology
Via
GlobeNewswire
Tickers
OLMA
Olema Oncology Announces Combined Financing for Up to $180 Million
September 05, 2023
From
Olema Oncology
Via
GlobeNewswire
Tickers
OLMA
Olema Oncology Reports Second Quarter 2023 Financial Results and Provides Corporate Update
August 08, 2023
From
Olema Oncology
Via
GlobeNewswire
Tickers
OLMA
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 02, 2023
From
Olema Oncology
Via
GlobeNewswire
Tickers
OLMA
Olema Oncology to Present at the Canaccord Genuity 43rd Annual Growth Conference
August 01, 2023
From
Olema Oncology
Via
GlobeNewswire
Tickers
OLMA
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 05, 2023
From
Olema Oncology
Via
GlobeNewswire
Tickers
OLMA
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 02, 2023
From
Olema Oncology
Via
GlobeNewswire
Tickers
OLMA
Olema Oncology to Present at the 2023 Jefferies Healthcare Conference
May 30, 2023
From
Olema Oncology
Via
GlobeNewswire
Tickers
OLMA
Olema Oncology Announces OP-1250 Continues to Demonstrate Attractive Combinability with CDK4/6 Inhibitor Palbociclib in Phase 1b/2 Study
May 11, 2023
From
Olema Oncology
Via
GlobeNewswire
Tickers
OLMA
Olema Oncology Reports First Quarter 2023 Financial Results and Provides Corporate Update
May 09, 2023
From
Olema Oncology
Via
GlobeNewswire
Tickers
OLMA
Olema Oncology Announces Upcoming Poster Presentation at the 2023 ESMO Breast Cancer Annual Congress
May 08, 2023
From
Olema Oncology
Via
GlobeNewswire
Tickers
OLMA
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 02, 2023
From
Olema Oncology
Via
GlobeNewswire
Tickers
OLMA
Olema Oncology to Participate in Canaccord Genuity 2023 Horizons in Oncology Virtual Conference
April 13, 2023
From
Olema Oncology
Via
GlobeNewswire
Tickers
OLMA
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 04, 2023
From
Olema Oncology
Via
GlobeNewswire
Tickers
OLMA
Olema Oncology Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Strategic Update
March 09, 2023
From
Olema Oncology
Via
GlobeNewswire
Tickers
OLMA
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 02, 2023
From
Olema Oncology
Via
GlobeNewswire
Tickers
OLMA
Olema Oncology to Present at Oppenheimer 33rd Annual Healthcare Conference
March 02, 2023
From
Olema Oncology
Via
GlobeNewswire
Tickers
OLMA
Olema Oncology to Participate at Upcoming Investor Conferences
February 21, 2023
From
Olema Oncology
Via
GlobeNewswire
Tickers
OLMA
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.